Image de couverture de livre

Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Ioannis Alagkiozidis (Auteur), Melissa Lozano (Auteur), Mithun Devraj (Auteur), Yi-Chun Lee (Auteur), Ovadia Abulafia (Auteur)
Format:	Livre
Publié:	Elsevier, 2015-04-01T00:00:00Z.
Sujets:	article
Accès en ligne:	Connect to this object online.
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
par: Rose Isono-Nakata, et autres
Publié: (2018)

Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study
par: Roze Isono-Taniguchi, et autres
Publié: (2022)

Metronomic therapy for gynecologic cancers
par: Wen-Hsiang Su, et autres
Publié: (2012)

Clinical Applications of Metronomic Chemotherapy
Publié: (2023)

Metronomics: Intrinsic Anakoinosis Modulator?
par: André Nicolas, et autres
Publié: (2018)

Pembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series
par: Shannon M. Glynn, et autres
Publié: (2024)

Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives
par: Vijay Kumar Panthi, et autres
Publié: (2023)

Oral metronomic therapy in head and neck cancer
par: Vinod Sharma, et autres
Publié: (2021)

Oral metronomic therapy in head and neck cancer
par: Raja Pramanik, et autres
Publié: (2021)

Oral uracil and tegafur as postoperative adjuvant metronomic chemotherapy in patients with advanced oral squamous cell carcinoma
par: Jiun-Sheng Lin, et autres
Publié: (2015)

A New Bevacizumab Carrier for Intravitreal Administration: Focus on Stability
par: Daniela Chirio, et autres
Publié: (2021)

Oral metronomic therapy in head and neck cancer - Authors' reply
par: Vijay Patil, et autres
Publié: (2021)

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
par: Ruby Maharjan, et autres
Publié: (2019)

The metronome-based methodology to monitor the stroke length changes in trained swimmers
par: Marco Fassone, et autres
Publié: (2023)

Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer
par: Samantha Cohen, et autres
Publié: (2019)

PENGGUNAAN METRONOM LAMPU UNTUK MENINGKATKAN KOORDINASI GERAK TARI SISWA TUNARUNGU
par: Tupan, Noviardi
Publié: (2014)

Bevacizumab for glioblastoma
par: Narita Y
Publié: (2015)

Downstaging with atezolizumab-bevacizumab: a case series
par: Anand V. Kulkarni, et autres
Publié: (2024)

The use of a metronome during cardiopulmonary resuscitation in the emergency room of a university hospital
par: Renata Maria de Oliveira Botelho, et autres

Metronomic 5-Fluorouracil Delivery Primes Skeletal Muscle for Myopathy but Does Not Cause Cachexia
par: Dean G. Campelj, et autres
Publié: (2021)

Is the routine use of bevacizumab in the treatment of women with advanced or recurrent cancer of the cervix sustainable?
par: Klag N, et autres
Publié: (2016)

Breast metastases: A rare manifestation of advanced uterine serous carcinoma
par: Jennifer McEachron, et autres
Publié: (2019)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
par: Ping-Chih Hsu, et autres
Publié: (2020)

Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity
par: Ruby Maharjan, et autres
Publié: (2021)

Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients
par: Soshi Kusunoki, et autres
Publié: (2018)

Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis
par: Wanjun Tao, et autres
Publié: (2020)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
par: Tae Hyun Kim, et autres
Publié: (2023)

Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies
par: Shu-Ping Lee, et autres
Publié: (2019)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
par: Di Cao, et autres
Publié: (2023)

Bevacizumab-Induced Geographic Tongue
par: Marta Martinez-Garcia, et autres
Publié: (2021)

Monitoring antiangiogenesis of bevacizumab in zebrafish
par: Zhang J, et autres
Publié: (2018)

Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer
par: Taraswi Mitra Ghosh, et autres
Publié: (2021)

Hexachlorobenzene as a differential modulator of the conventional and metronomic chemotherapy response in triple negative breast cancer cells
par: Yamila Sanchez, et autres
Publié: (2024)

A One Session Gait Retraining Protocol with Metronome Augmentation Increases Cadence in Novice and Recreational Runners
par: Angie Huber, et autres
Publié: (2024)

Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
par: Madison R. Klavans, et autres
Publié: (2020)

Lipidomics of cyclophosphamide 4‐hydroxylation in patients receiving post‐transplant cyclophosphamide
par: Sandi L. Navarro, et autres
Publié: (2022)

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain
par: Lister J, et autres
Publié: (2012)

Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab
par: Suemin Park, et autres
Publié: (2024)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
par: Qingli Cui, et autres
Publié: (2022)

Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
par: Chun-Hua Zhou, et autres
Publié: (2021)